Navigation Links
Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
Date:6/22/2011

JERUSALEM, Israel, June 22, 2011 /PRNewswire/ --


 

Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a biotech company with a novel platform technology for the oral delivery of drugs currently only available via injection, announced today that Dr. Michael Berelowitz, M.D., has been appointed the Chairman of its Scientific Advisory Board (SAB).

Dr. Berelowitz joined Oramed's Board of Directors in May 2010 and will now expand his role as Chairman of the SAB.  Moving forward, he will be actively involved in the Company's scientific decisions, clinical strategy, and partnership negotiations.  

Dr. Berelowitz has extensive experience as an academic endocrinologist as well as expertise in clinical research and drug development.  Most recently, he served as the Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit at Pfizer.  Dr. Berelowitz joined Pfizer in 1996, after several years in academia, as a Medical Director on the Diabetes Disease Management Team. Among his public activities, Dr. Berelowitz has served on the board of directors of the American Diabetes Association and the Clinical Initiatives Committee of the Endocrine Society.  He has also chaired the Task Force on Research of the New York State Council on Diabetes and has served on several editorial boards. Dr. Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in the areas of pituitary growth hormone regulation, diabetes and metabolic disorders.

"Dr. Berelowitz is a renowned industry leader with a special interest in and knowledge of diabetes. His expertise in this expanded role will be invaluable as Oramed continues to advance its clinical trials and business development efforts," said Nadav Kidron, Chief Executive Officer of Oramed.

Dr. Berelowitz commented, "I am honored and excited about m
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
2. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
3. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
4. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
5. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
6. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
7. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
8. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
9. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
10. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
11. Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... doubled Hectorol sales , Middleton, Wis. Bone ... the work of University of Wisconsin-Madison professor Hector DeLuca, reported ... said its sales of the drug Hectorol were $19.6 million, ... million, despite large theft , Neenah, Wis. ...
... Actor Michael J. Fox plans to visit the Waisman ... Jim Doyle and Fox will hold a media event ... for biotechnology research in Wisconsin. , ,In November, Doyle ... biotechnology and stem cell research, including a collective $750 ...
... wrote about the importance of transparency, which I described ... and maybe even personal perspectives" so that "intelligent consumers ... and write." , ,This transparency puts content in context, ... where the rules of reportorial journalism, more often than ...
Cached Biology Technology:Michael J. Fox coming to UW Waisman Center 2Corporations and blogging 2Corporations and blogging 3
(Date:4/23/2014)... This news release is available in French ... , Montreal, 23 April 2014Today, the CEC released ... A Binational Collaborative Approach to Conservation, which identifies 29 ... States-Mexico border that includes 11 different protected areas in ... features unique, highly diverse arid and semi-arid habitats inhabited ...
(Date:4/23/2014)... NY. (Apr. 23, 2014) People who have had ... to restore neurological function. However, a study conducted in ... of Cell Transplantation , but is currently freely ... http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one group of ... (PBSCs) injected directly into the brain and a similar ...
(Date:4/23/2014)... in Buenos Aires yesterday, Argentina joins the European ... state. The move strengthens the ties between the ... grants Argentinian scientists access to EMBL,s world-class facilities ... "Ever since its inception, fostering excellent life science ... the core of EMBL,s mission," says EMBL Director ...
Breaking Biology News(10 mins):Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Autologous stem cell therapy improves motor function in chronic stroke victims 2
... new protein produced excessively in malignant melanoma, a discovery ... dramatically among young women. The protein, IMP-3, is ... the most dangerous types of skin cancer, and in ... predict called thin melanomas. The finding offers a potential ...
... DAGAN, ISRAEL - Table grapes are subject to serious water ... vine to dinner tables around the world. Mold and browning ... grape quality during shipping and storage in retail produce sections. ... one way of ensuring that consumers get fresh, appealing fruits. ...
... Washington, DCMay 28, 2008The 2008 American Society ... the Year Award is presented to Vctor ... of Biotechnology of the Spanish Research Council, ... microbiologist who has exhibited exemplary leadership in ...
Cached Biology News:As rates rise, researchers find better way to identify melanoma 2As rates rise, researchers find better way to identify melanoma 3Fresh from the grapevine to the table 2American Society for Microbiology honors Victor de Lorenzo 2
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
...
...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
Biology Products: